Andere Sprachen Atea Pharmaceuticals, Inc.

Aktien

A2QGE7

US04683R1068

AVIR

Realtime-Estimate Cboe BZX Andere Börsenplätze 20:17:42 02.07.2024			% 5 Tage	% 1. Jan.
3.315 ^USD	-1.63%		-3.50%	+8.52%

05.06.	Atea Pharmaceuticals präsentiert auf dem EASL-Kongress 2024 positive erste Phase-2-Daten für die Kombination von Bemnifosbuvir und Ruzasvir zur Behandlung des Hepatitis-C-Virus	CI
22.05.	Atea Pharmaceuticals präsentiert auf dem EASL-Kongress 2024 neue Daten, die das potenziell klassenbeste Kombinationsprofil von Bemnifosbuvir und Ruzasvir zur Behandlung des Hepatitis-C-Virus zeigen	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Atea Pharmaceuticals : Jefferies Global Healthcare Conference Presentation	05.06.
Atea Pharmaceuticals : Absorption, Distribution, Metabolism, and Excretion of Bemnifosbuvir in Rats (SAT 411)	05.06.
Atea Pharmaceuticals : Lead in Cohort Results From a Phase 2 Study of a Novel 8 Week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients with Chronic Hepatitis C Virus Infection (THU 382)	05.06.
Atea Pharmaceuticals : Low Risk of Drug Drug Interactions for Ruzasvir Based Upon In Vitro Metabolism and Transporter Interaction Studies (SAT 412)	05.06.
Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024	05.06.
Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024	05.06.
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference	29.05.
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024	22.05.
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024	22.05.
Atea Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14.05.
Atea Pharmaceuticals : First Quarter 2024 Financial Results Conference Call Presentation	14.05.
Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update	14.05.
Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024	07.05.
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024	29.04.
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients	27.03.
Atea Pharmaceuticals, Inc. Completes Patient Enrollment in Global Phase 3 Sunrise-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients	27.03.
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.02.
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28.02.
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	28.02.
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024	21.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Atea Pharmaceuticals, Inc.

Aktien

A2QGE7

US04683R1068

AVIR

Andere Sprachen

Filter